The Centers for Medicare & Medicaid Services has proposed three national coverage determinations (NCDs) to establish uniform national policies designed to prevent Medicare from paying for certain ...

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous ...

In a session held during the Florida Society of Clinical Oncology’s annual meeting in April, panelist James Almas, MD, vice president and national medical director of clinical effectiveness at LabCorp ...

The Centers for Medicare and Medicaid Services said this week it's opening a National Coverage Determination analysis, a process that will allow the agency to review and determine whether Medicare ...

We examined Medicare national coverage determinations for medical interventions to determine whether or not they have become more restrictive over time. National coverage determinations address ...

Coverage determination for oncology drugs can be delayed for months after regulatory approval, a new study suggests. Coverage determination for oncology drugs can be delayed for months after ...

Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring SAN CARLOS, Calif., Sept.

We examined Medicare national coverage determinations for medical interventions to determine whether or not they have become more restrictive over time. National coverage determinations address ...